William Blair Reiterates Outperform Rating on ARS Pharmaceuticals Inc (SPRY) following Q4 results

March 9, 2026 8:01 AM EDT Send to a Friend
William Blair analyst Tim Lugo reiterated an Outperform rating on ARS Pharmaceuticals Inc (NASDAQ: SPRY)The analyst commented, "While we acknowledge ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login